Search

Search Constraints

You searched for: Author/Creator Rizzieri, David

Search Results

1. 355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies. (10th December 2020)

2. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. (25th April 2017)

3. A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma. (19th March 2013)

4. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Issue 9 (September 2014)

5. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. (August 2020)

7. Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma. (16th March 2023)

8. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Issue 4 (21st October 2020)

9. Cyclophosphamide‐based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. Issue 3 (8th October 2014)

10. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Issue 2 (6th December 2017)